News
Majority of US women agree there isn’t enough focus on postpartum healthcare
New research reveals significant shortcomings in the health information and support women in the US receive during pregnancy and postpartum.
The State of Maternal Health Report, conducted by The Harris Poll in April, showed that pregnant women in the US are being underserved when it comes to postpartum education and support.
Two in five women who have been pregnant (40 per cent) reported receiving insufficient (22 per cent) or no information/ resources at all (18 per cent) from their healthcare providers (HCPs) on the topic of breastfeeding, according to the survey.
The gap widens when it comes to mental health, with more than half of women who have been pregnant (53 per cent) likely under-supported as they did not receive any (40 per cent) or enough (13 per cent) information on postpartum depression.
“These statistics are not just numbers; they represent the real struggles of mothers nationwide, including myself, who feel neglected by the systems meant to support them,” said Christina Lojek, research manager at The Harris Poll.
“Fuelled by my own experiences, I chose to lead this study, and it solidifies how imperative it is that we improve postpartum support and education for mothers, who are clearly asking for and deserving of much better care.”
Lack of education on postpartum depression is even more distressing given how much more widespread this health issue is becoming. About one in eight women who are currently pregnant or have been pregnant (13 per cent) say they were diagnosed with postpartum depression by a medical professional – this jumps to 29 per cent among women ages 18-34, versus 10 per cent among women 35 and over.
The need for better postpartum care is also evident. Roughly one in four women who have been pregnant (24 per cent) rated their postpartum care as less than adequate.
Postpartum care appears to be on the decline, with over a third of women ages 18-34 who have been pregnant (36 per cent) citing subpar care, compared to just 22 per cent of women 35 and over.
Additionally, a substantial 74 per cent of all women agree that there isn’t enough focus on postpartum healthcare for mothers, and nearly two thirds (64 per cent) feel that mothers are often forgotten once the baby arrives.
Another significant way that women are being neglected postpartum is the lack of federal maternity leave in the US. The report highlighted a strong consensus on the importance of maternity leave, with nearly all women affirming its pivotal role in improving health outcomes.
Despite this, dissatisfaction with US maternity leave policies is evident, as a significant majority of women (73 per cent) consider the leave provided by most US employers insufficient. Nearly three in five women believe that the standard minimum length of paid maternity leave should be extended to at least 12 weeks, with about a quarter advocating for 20 weeks or more.
Lojek said: “This should be a wake-up call for all stakeholders involved in maternal healthcare to strengthen support structures and ensure mothers receive the care and information they need to safeguard the health and wellbeing of both mothers and their children.”
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment